loading page

Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial British R3 chemotherapy
  • +1
  • Zhongbo Hu,
  • Kristen VanHeyst,
  • Jignesh Dalal,
  • Lisa Hackney
Zhongbo Hu
UH Rainbow Babies and Children's Hospital
Author Profile
Kristen VanHeyst
UH Rainbow Babies and Children's Hospital
Author Profile
Jignesh Dalal
UH Rainbow Babies and Children's Hospital
Author Profile
Lisa Hackney
UH Rainbow Babies and Children's Hospital
Author Profile

Abstract

DS-ALL patients have a higher rate of relapse and treatment-related mortality. We describe a DS-ALL patient with late bone marrow relapse who was treated per British ALL R3 reinduction chemotherapy. The patient remained in remission for approximately two years after therapy was discontinued due to severe systemic infections.

Peer review status:Published

05 Sep 2020Submitted to Clinical Case Reports
07 Sep 2020Submission Checks Completed
07 Sep 2020Assigned to Editor
13 Sep 2020Reviewer(s) Assigned
21 Oct 2020Review(s) Completed, Editorial Evaluation Pending
28 Oct 2020Editorial Decision: Revise Minor
11 Nov 20201st Revision Received
16 Nov 2020Submission Checks Completed
16 Nov 2020Assigned to Editor
16 Nov 2020Review(s) Completed, Editorial Evaluation Pending
27 Nov 2020Editorial Decision: Accept
12 Feb 2021Published in Clinical Case Reports. 10.1002/ccr3.3678